Recommendations for the management of behavioral and psychological symptoms of dementia

Canadian Journal of Neurological Sciences

Volumn 28, Issue SUPPL. 1, 2001, Pages

  Herrmann, N ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LORAZEPAM; LOXAPINE; OLANZAPINE; OXAZEPAM; PAROXETINE; PERPHENAZINE; PINDOLOL; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TIOTIXENE; TRAZODONE; TRIFLUOPERAZINE; VALPROIC ACID;

AGGRESSION; AGITATION; BEHAVIOR DISORDER; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DEMENTIA; DRUG EFFICACY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MEDICAL LITERATURE; MENTAL DISEASE; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0035107116     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100001268     Document Type: Conference Paper

References (197)

1. Behavioral and psychological signs and symptoms of dementia. Implications for research and treatment
2. Criteria for the clinical diagnosis of Alzheimer's disease
3. Alois Alzheimer on presenile dementia
4. The impact of dementia on the family
5. Management of behaviour disturbance in Alzheimer's disease: Current knowledge and future direction
6. Delirium and dementia. Diagnostic criteria and fatality rates
7. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment
8. The psychiatric symptoms of Alzheimer's disease
9. Behavioral disturbance in dementia of the Alzheimer's type
10. Overview of depression and psychosis in Alzheimer's disease
11. Global deterioration scale (GDS)
12. Pharmacologic approach to management of agitation associated with dementia
13. Disruptive behaviour in elderly nursing home residents: A survey of nursing staff
14. Behavioral problems among patients in skilled nursing facilities
15. Troublesome and disruptive behaviours in dementia: Relationship to diagnosis and disease severity
16. Assessment of cognitive, psychiatric and behavioral disturbances in patients with dementia: The neurobehavioral rating scale
17. The spectrum of behavioral changes in Alzheimer's disease
18. Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content
19. Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception
20. Psychiatric phenomena in Alzheimer's disease. III. Disorders of mood
21. Psychiatric phenomena in Alzheimer's disease. IV. Disorders of behaviour
22. Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type
23. Clinical and neuropathological criteria for frontotemporal dementia
24. Lewy body dementia - Diagnosis and treatment
25. Aggressive behaviour in persons with dementia who live in the community
26. Dementia: The experience of family caregivers
27. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
28. Assessing the clinical effectiveness of preventative manoeuvres: Analytical principles and systematic methods in reviewing evidence and developing clinical practice recommendations
29. The recognition, assessment and management of dementing disorders: Conclusions from the Canadian Consensus Conference on Dementia
30. Sensory deficits and mental disorders of old age: Causal or coincidental associations?
31. The relationship between vision impairment and the assessment of disruptive behaviours among nursing home residents
32. Association among visual hallucinations, visual acuity and specific eye pathologies in Alzheimer's disease: Treatment implications
33. Psychotropic drugs and the elderly patient
34. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life
35. Measures of psychiatric symptoms in Alzheimer patients: A review
36. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician
37. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia
38. Agitated behaviours in the elderly. I. A conceptual review
39. Agitated behaviours in the elderly. II. Preliminary results in the cognitively deteriorated
40. Aggressive behaviour in hospitalized psychogeriatric patients
41. Staff observation aggression scale, SOAS. Presentation and evaluation
42. Interventions for treating disruptive behaviour in demented elderly people
43. Management of behaviour problems in the demented patient
44. Interventions for the behavioral complications of Alzheimer's disease: Behavioral approaches
45. The efficacy of psychosocial approaches to behavior disorders in dementia: A systematic literature review
46. Modifying repetitive verbalizations of community-dwelling patients with AD
47. A randomized trial of dementia care in nursing homes
48. A reduced stimulation unit: Effects on patients with Alzheimer's disease and related disorders
49. Effects of environmental stimulation on biochemical and psychological variables in dementia
50. The effect of music on repetitive disruptive vocalizations of persons with dementia
51. Effects of individualized music on confused and agitated elderly patients
52. Effects of relaxing music on agitation during meals among nursing home residents with severe cognitive impairment
53. Dinner music for demented patients: Analysis of video-recorded observations
54. Environmental "white noise": An intervention for verbally agitated nursing home residents
55. Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease
56. Indirect bright light improves circadian rest-activity rhythm disturbances in demented patients
57. A randomized, controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care
58. Behavioral disturbances in demented elderly people
59. Application of operant procedures in a group of institutionalized aggressive geriatric patients
60. Behavioral analyses and nursing interventions for reducing disruptive behaviors of patients with dementia
61. Behavioral approaches to the treatment of Alzheimer's disease: Research strategies
62. Behavioural disorders in demented elderly patients: Current issues in pharmacotherapy
63. From transmitters to treatment: The pharmacotherapy of behavioural disturbances in dementia
64. Use of psychoactive medication and the quality of care in rest homes: Findings and policy implications of a state-wide study
65. Neuroleptic prescriptions for acutely ill geriatric patients
66. Improving medication prescribing and utilization in the nursing home
67. A longitudinal study of psychotropic prescriptions in a teaching nursing home
68. Aggressive behaviour in persons with dementia who live in the community
69. Effect of the Omnibus Reconciliation Act 1987 on antipsychotic prescribing in nursing home residents
70. Explicit criteria for determining inappropriate medication use in nursing home residents
71. Recent advances in geriatric psychopharmacology
72. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and aged-matched controls
73. Delirium in the elderly patient
74. Unnecessary use of tranquilizers in elderly patients
75. Dementia and antipsychotic drugs
76. Acute effects of neuroleptic withdrawal in elderly dementia patients
77. Reducing antipsychotic drug use in nursing homes. A controlled trial of provider education
78. Effects of antipsychotic withdrawal in elderly nursing home residents
79. Discontinuation of antipsychotics in nursing home patients with dementia
80. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents
81. The course of psychopathologic features in mild to moderate Alzheimer's disease
82. Management of the behavioral manifestations of dementia
83. Practical guidelines for the treatment of behavioral complications of dementia
84. Pharmacologic management of aggression in the elderly
85. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia
86. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease
87. Neuroleptic-induced parkinsonism in elderly patients diagnosed with psychotic major depression and dementia of the Alzheimer type
88. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up
89. Neuroleptic sensitivity in patients with senile dementia of Lewy body type
90. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: A preliminary study
91. Efficacy and adverse effects of clozapine in four elderly psychotic patients
92. Clozapine in older patients with psychosis and behavioral disruption
93. Olanzapine in dementia with Lewy bodies: A clinical study
94. Olanzapine use in the elderly: A retrospective analysis
95. Radioreceptor binding profile of atypical antipsychotic olanzapine
96. Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial
97. Quetiapine may reduce hostility in patients with psychosis related to Alzheimer's disease
98. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: A case series
99. Risperidone in the elderly: A pharmacoepidemiologic study
100. Risperidone for dementia-related disturbed behaviour in nursing home residents: A clinical experience
101. Risperidone for the treatment of behavioral disturbances in dementia
102. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
103. A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia
104. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
105. Tardive dyskinesia: A review
106. Nonneuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: A selective review
107. Trazodone for behavioral disturbances in Alzheimer's disease
108. A naturalistic study of trazodone in the treatment of behavioral complications of dementia
109. Behavioral effects of trazodone in Alzheimer's disease
110. Treatment of organic personality syndrome with low-dose trazodone
111. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease
112. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia
113. Pharmacologic treatment of noncognitive symptoms of dementia
114. Behavioral effects of fluoxetine in dementia of Alzheimer's type
115. Fluoxetine in dementia of the Alzheimer's type: Prominent adverse effects and failure to improve cognition
116. The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia
117. Fluvoxamine in the treatment of demented elderly patients: A double-blind placebo-controlled study
118. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A Nordic multicentre study
119. An open pilot study of citalopram for behavioral disturbances of dementia
120. Frontotemporal dementia: Treatment response to serotonin selective reuptake inhibitors
121. Brief information on an early phase II study with deprenyl in demented patients
122. A pilot study of low-dose l-deprenyl in Alzheimer's disease
123. The use of selegiline in Alzheimer's patients with behaviour problems
124. L-Deprenyl in Alzheimer's disease: Preliminary evidence for behavioral change with monoamine oxidase B inhibition
125. Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease
126. L-Deprenyl in the treatment of mild dementia of the Alzheimer type: Results of a 15-month trial
127. L-deprenyl in Alzheimer's disease: Cognitive and behavioral effects
128. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics
129. Carbamazepine treatment of agitation associated with dementia
130. Carbamazepine for assaultive patients with organic brain disease
131. A preliminary study of carbamazepine in the treatment of patients with dementia
132. Effects of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics
133. Carbamazepine in senile dementia and overactivity - A placebo controlled double blind trial. International Research Communication System
134. Carbamazepine treatment of agitation in nursing home patients with dementia: A preliminary study
135. Carbamazepine use in aggressive behaviour associated with senile dementia
136. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia
137. Sodium valproate in the treatment of behavioral disturbance in dementia
138. Valproic acid for physically aggressive behaviour in geriatric patients
139. The effects of sodium valproate on disturbed behaviour in dementia
140. Valproate treatment of older psychotic patients with organic mental syndromes and behavioral dyscontrol
141. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic
142. Valproic acid treatment of agitation in dementia
143. Gabapentin for behavioral agitation in Alzheimer's disease
144. Gabapentin in geriatric psychiatry patients
145. Gabapentin for disruptive behavior in an elderly demented patient
146. Gabapentin for the management of agitation
147. Treatment of dementia-associated agitation with gabapentin
148. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia
149. Treatment of agitation in older persons with dementia: The expert consensus guideline series
150. Propranolol in organic agitation
151. Propranolol in the treatment of assaultive patients with organic brain disease
152. Propranolol treatment of assaultive patients with organic brain disease
153. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: A double-blind study
154. Treatment of behavioral problems with pindolol
155. Propranolol for the control of disruptive behaviour in senile dementia
156. Non-neuroleptic treatment of disruptive behviour in organic mental syndromes
157. Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients
158. Management of behaviour in the institutionalized aged
159. Blind study of oxazepam in the management of geriatric patients with behavioral problems
160. Evaluation of oxazepam and placebo in emotionally disturbed aged patients
161. Comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility: Double-blind study
162. Alleviating agitation, apprehension and related symptoms in geriatric patients: A double-blind comparison of phenothiazine and a benzodiazepine
163. Multicenter study comparing thioidazine with diazepam and placebo in elderly nonpsychotic patients with emotional and behavioral disorders
164. Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients
165. The use of benzodiazepines in the management of behavioral symptoms in demented patients
166. Clonazepam treatment of organic brain syndromes in three elderly patients
167. Clonazepam treatment of multi-infarct dementia
168. Clonazepam for agitated patients with Alzheimer's disease
169. Buspirone in treatment of agitated demented patient
170. Buspirone in the management of agitation and aggression associated with dementia
171. Effects of buspirone on agitation associated with dementia
172. A trial of buspirone for the control of disruptive behaviours in community dwelling patients with dementia
173. Buspirone vs haloperidol: A double-blind trial for agitation in a nursing home population with Alzheimer's disease
174. Cholinesterase inhibitors: A new class of psychotropic compounds
175. A controlled trial of tacrine in Alzheimer's disease
176. A double-blind placebo controlled multicentre study of tacrine for Alzheimer's disease
177. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
178. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
179. Physostigmine ameliorates the delusions of Alzheimer's disease
180. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease
181. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer's disease
182. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease
183. Donepezil for behavioral disorders associated with Lewy bodies: A case series
184. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
185. Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer's disease
186. Medroxyprogestrone acetate (MPA) treatment of sexual acting out in men suffering from dementia
187. The use of oestrogen to decrease aggressive physical behaviour in elderly men with dementia
188. Normalization of sexual behaviour in a female with dementia after treatment with cyproterone
189. Leuprolide acetate for exhibitionism in Huntington's disease
190. Leuprolide treatment of sexual aggression in a patient with dementia and the kluver-bucy syndrome
191. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia
192. Ondansetron for hallucinosis in advanced Parkinson's disease
193. Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5HT3 receptor antagonist
194. Effects of dronabinol on anorexia and disturbed behaviour in patients with Alzheimer's disease
195. ECT: An effective treatment in the screaming demented patient
196. Efficacy of ECT for agitation in dementia